TY - JOUR
T1 - Neurotoxins
T2 - Expanding uses of neuromodulators in medicine-major depressive disorder
AU - Magid, Michelle
AU - Keeling, Brett H.
AU - Reichenberg, Jason S.
PY - 2015
Y1 - 2015
N2 - Background: Botulinum toxin A (BTA) is one of the most diversely used medications of the 21st century and is now being researched as a treatment for major depressive disorder (MDD). Methods: The authors performed a literature search of PubMed, Web of Science, and the Cochrane Register of Controlled Trials. The primary investigators of the studies were contacted for additional unpublished data. Results: The authors identified 5 studies that met the criteria of using BTA in the treatment of MDD. All studies showed significant reduction in depressive symptoms with BTA injected into the glabellar muscles. In a pooled analysis, botulinum toxin (n = 59) vs placebo (n = 75) had a -47% vs -16% reduction in self-rated depression scores (P <0.0001) and a -46% vs -15% reduction in expert-rated depression scores (P <0.0001), respectively. Adverse reactions were mild (temporary headaches and local irritation immediately after injection) and did not differ between active group (13.6%) and placebo group (9.3%) (P = 0.44). Conclusions: Botulinum toxin injections in the glabellar frown muscles have been associated with a significant improvement in depressive symptoms. Given the prevalence of MDD, the promising results of preliminary trials, and the excellent tolerability of this treatment intervention, larger studies are warranted.
AB - Background: Botulinum toxin A (BTA) is one of the most diversely used medications of the 21st century and is now being researched as a treatment for major depressive disorder (MDD). Methods: The authors performed a literature search of PubMed, Web of Science, and the Cochrane Register of Controlled Trials. The primary investigators of the studies were contacted for additional unpublished data. Results: The authors identified 5 studies that met the criteria of using BTA in the treatment of MDD. All studies showed significant reduction in depressive symptoms with BTA injected into the glabellar muscles. In a pooled analysis, botulinum toxin (n = 59) vs placebo (n = 75) had a -47% vs -16% reduction in self-rated depression scores (P <0.0001) and a -46% vs -15% reduction in expert-rated depression scores (P <0.0001), respectively. Adverse reactions were mild (temporary headaches and local irritation immediately after injection) and did not differ between active group (13.6%) and placebo group (9.3%) (P = 0.44). Conclusions: Botulinum toxin injections in the glabellar frown muscles have been associated with a significant improvement in depressive symptoms. Given the prevalence of MDD, the promising results of preliminary trials, and the excellent tolerability of this treatment intervention, larger studies are warranted.
UR - http://www.scopus.com/inward/record.url?scp=84943739429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943739429&partnerID=8YFLogxK
U2 - 10.1097/PRS.0000000000001733
DO - 10.1097/PRS.0000000000001733
M3 - Article
C2 - 26441090
AN - SCOPUS:84943739429
SN - 0032-1052
VL - 136
SP - 111S-119S
JO - Plastic and Reconstructive Surgery
JF - Plastic and Reconstructive Surgery
IS - 5
ER -